Nature Communications (Feb 2021)
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
- Cristina Valero,
- Mark Lee,
- Douglas Hoen,
- Kate Weiss,
- Daniel W. Kelly,
- Prasad S. Adusumilli,
- Paul K. Paik,
- George Plitas,
- Marc Ladanyi,
- Michael A. Postow,
- Charlotte E. Ariyan,
- Alexander N. Shoushtari,
- Vinod P. Balachandran,
- A. Ari Hakimi,
- Aimee M. Crago,
- Kara C. Long Roche,
- J. Joshua Smith,
- Ian Ganly,
- Richard J. Wong,
- Snehal G. Patel,
- Jatin P. Shah,
- Nancy Y. Lee,
- Nadeem Riaz,
- Jingming Wang,
- Ahmet Zehir,
- Michael F. Berger,
- Timothy A. Chan,
- Venkatraman E. Seshan,
- Luc G. T. Morris
Affiliations
- Cristina Valero
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Mark Lee
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Douglas Hoen
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Kate Weiss
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Daniel W. Kelly
- Information Systems, Memorial Sloan Kettering Cancer Center
- Prasad S. Adusumilli
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Paul K. Paik
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- George Plitas
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Marc Ladanyi
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Michael A. Postow
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Charlotte E. Ariyan
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Alexander N. Shoushtari
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Vinod P. Balachandran
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- A. Ari Hakimi
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Aimee M. Crago
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Kara C. Long Roche
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- J. Joshua Smith
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Ian Ganly
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Richard J. Wong
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Snehal G. Patel
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Jatin P. Shah
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- Nancy Y. Lee
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center
- Nadeem Riaz
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Jingming Wang
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Ahmet Zehir
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Michael F. Berger
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Timothy A. Chan
- Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center
- Venkatraman E. Seshan
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center
- Luc G. T. Morris
- Department of Surgery, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-021-20935-9
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 9
Abstract
There is an unmet clinical need for simple, accessible biomarkers to select patients who are more likely to respond to immune checkpoint therapy. Here the authors show that a lower neutrophil-to-lymphocyte ratio is associated with better overall and progressive-free survival, as well as higher rate of response, in a multi-cancer cohort of patients treated with immune checkpoint inhibitors.
